A harmonized meta-knowledgebase of clinical interpretations of cancer genomic variants

Wagner, A. H.; Walsh, B.; Mayfield, G.; Tamborero, D.; Sonkin, D.; Krysiak, K.; Deu Pons, J.; Duren, R.; Gao, J.; McMurry, J.; Patterson, S.; Del Vecchio Fitz, C.; Sezerman, O. U.; Warner, J.; Rieke, D. T.; Aittokallio, T.; Cerami, E.; Ritter, D.; Schriml, L. M.; Haendel, M.; Raca, G.; Madhavan, S.; Baudis, M.; Beckmann, J. S.; Dienstmann, R.; Chakravarty, D.; Li, X. S.; Mockus, S. M.; Elemento, O.; Schultz, N.; Lopez-Bigas, N.; Lawler, M.; Goecks, J.; Griffith, M.; Griffith, O. L.; Margolin, A.

doi:10.1101/366856

Home/Archive/bioRxiv

bioRxiv · 10.1101/366856

A harmonized meta-knowledgebase of clinical interpretations of cancer genomic variants

View original source ↗Export metadata ↓

Abstract

Precision oncology relies on the accurate discovery and interpretation of genomic variants to enable individualized diagnosis, prognosis, and therapy selection. We found that knowledgebases containing clinical interpretations of somatic cancer variants are highly disparate in interpretation content, structure, and supporting primary literature, impeding consensus when evaluating variants and their relevance in a clinical setting. With the cooperation of experts of the Global Alliance for Genomics and Health (GA4GH) and six prominent cancer variant knowledgebases, we developed a framework for aggregating and harmonizing variant interpretations to produce a meta-knowledgebase of 12,856 aggregate interpretations covering 3,437 unique variants in 415 genes, 357 diseases, and 791 drugs. We demonstrated large gains in overlap between resources across variants, diseases, and drugs as a result of this harmonization. We subsequently demonstrated improved matching between a patient cohort and harmonized interpretations of potential clinical significance, observing an increase from an average of 33% per individual knowledgebase to 56% in aggregate. Our analyses illuminate the need for open, interoperable sharing of variant interpretation data. We also provide an open and freely available web interface (search.cancervariants.org) for exploring the harmonized interpretations from these six knowledgebases.

Source connections

Published article ↗

Explore related subjects

bioinformatics Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Wagner, A. H., Walsh, B., Mayfield, G., Tamborero, D., Sonkin, D., Krysiak, K., Deu Pons, J., Duren, R., Gao, J., McMurry, J., Patterson, S., Del Vecchio Fitz, C., Sezerman, O. U., Warner, J., Rieke, D. T., Aittokallio, T., Cerami, E., Ritter, D., Schriml, L. M., Haendel, M., Raca, G., Madhavan, S., Baudis, M., Beckmann, J. S., Dienstmann, R., Chakravarty, D., Li, X. S., Mockus, S. M., Elemento, O., Schultz, N., Lopez-Bigas, N., Lawler, M., Goecks, J., Griffith, M., Griffith, O. L., Margolin, A.. 2018-07-11. A harmonized meta-knowledgebase of clinical interpretations of cancer genomic variants. https://doi.org/10.1101/366856

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Transcript quantification using context-aware MAPQ modeling

Long-read RNA-sequencing enables accurate transcript-level quantification, but prior static filtering of MAPping Quality (MAPQ) can ignore transcriptome-intrinsic ambiguity, and discarding reads on this basis distorts abundance estimates. We present CALMeR (Context-Aware Long-read MAPQ-based Rescuer), which conditions MAPQ filtering on transcript properties rather than a fixed cutoff. CALMeR fits a zero-one inflated beta regression on various transcript and read-level features to model the expected MAPQ distribution for each alignment. Reads whose MAPQ fits this context, such as low-MAPQ reads from multi-isoform genes and paralog families are retained; reads with anomalously low MAPQ are removed as likely artifacts. Retained reads can be summed per transcript or passed to any downstream quantifier. Compared with a MAPQ [≥] 1 filter and expectation-maximization-based transcript quantification methods, CALMeR recovers more spike-in transcripts and better matches known spike-in concentrations. CALMeR is available at https://github.com/sparthib/CALMeR.

bioinformatics↗

bioRxiv2026

Structure-resolved fold annotation of the medicinal-leech salivary-EV cargo: a Ly-6/uPAR three-finger scaffold and a structurally dark fraction

Many proteins that medicinal leeches package into salivary extracellular vesicles (EVs) carry no interpretable sequence annotation, so the least-characterised part of a pharmacologically important secretome lacks even a fold assignment. A companion Astral-DIA study of Hirudinaria manillensis nominated 17 ultra-enriched candidate EV cargo proteins. Here we ask whether structure prediction and structural search can assign folds where sequence methods fail, and which candidates remain unresolved under prespecified criteria. With an offline pipeline (ESMFold, TM-align, Foldseek against AFDB-SwissProt and PDB100, UniRef90 search, protein-to-genome alignment), the candidates separate into intracellular/membrane machinery and a secreted, cysteine-dense fraction of three proteins with no Pfam domain. The predicted structure of the leech Protein-sleepless homolog g21166 supports its assignment to the Ly-6/uPAR three-finger fold (TM 0.58 vs CD59; best significant PDB match Lynx1); no function is inferred. g436 and g20791 returned no match meeting the criterion (alnTM [≥] 0.5, E [≤] 0.05) in either database, g436 even after homolog-informed modelling. Gene structure and splice junctions support a conserved locus for the two-Trypsin-segment model g8114 (catalytic unit not established). A Boltz-2 thrombin pilot did not support target engagement, and a pre-registered nicotinic test was terminated as undecidable. The results yield a structure-informed shortlist for experimental follow-up.

bioinformatics↗

bioRxiv2026

EpiRank: partner-agnostic surface-patch retrieval for epitope prediction of protein binding interfaces

Structure-based interface predictors are normally reported as a single pooled ROC AUC over a residue test set. For a protein designer the operative question is different and much harder: given one target chain, will the top-ranked surface patch be a real binding site? We built EpiRank, a partner-agnostic epitope predictor, on HumanPPI 29,246 predicted human dimers, 12,296 target chains, 4.18 M residues using only single-chain geometry and physicochemistry (170 features, no partner, no sequence search, no structural alphabet), and evaluated it as a retrieval problem with homology- and partner-graph-controlled splits, on the 3,529 chains that survive an explicit partner-contamination filter. The model places a real epitope in its top-ranked patch 64 % of the time. That number is far less informative than it looks. Compact patches placed at random hit a real epitope 41 % of the time under the same rule, so the model's lift is 1.57 x, not 64 %; 54 % of all predicted patches land on nothing; and when the same chains are scored by models trained on a 2,000-chain and an 11,669-chain superset, a substantial fraction change answer while the aggregate barely moves. We document four specific ways this task invites overstatement partner-graph percolation across splits, single-linkage homology percolation at the conventional 30 % identity threshold, a count-only hit rule that rewards spatial smoothing rather than signal, and hotspot precision conditioned on success, which ranks a random baseline above the trained model. Each was hit during development and each inverted a conclusion we had already drawn. We argue that interface-prediction papers should report lift over a geometry-matched random baseline, patch precision, and per-target stability alongside AUC, and we release the evaluation harness that computes them.

bioinformatics↗